

Multidisciplinary Hepatocellular and Metastatic Liver Tumor Case Conference

Provided by Rutgers New Jersey Medical School, Department of Radiology

Interesting Cases of the Week

Held virtually via WebEx

8/27/2024

12:30PM to 2:00PM



Inessa Goldman, MD

Assistant Professor, Rutgers New Jersey Medical School

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Identify the common presentation and management of varied liver diseases, hepatocellular carcinoma, and other hepatobiliary tumors.
- Recognize the varied imaging modalities available to direct diagnosis and treatment, as well as limitations of each.
- Review the optimal and adjuvant roles hepatology, interventional radiology and hepatobiliary surgery take in treatment of these diseases.
- Determine treatment algorithms for patients with HCC
- Assess which patients are eligible for and will benefit from liver transplant
- Assess which patients are eligible for and will benefit from image guided intervention (TIPS, RFA, Y90, stenting)
- Compare varying imaging modalities which will best evaluate the clinical issue

Target Audience

This activity is designed for radiologists, surgeons, internists, physician assistants, medical students, and radiology residents.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Inessa Goldman, MD has no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee:

Drs. Chaudhry, Paterno, Niazi, and Ignazio Dimino, Elisabete DaSilva have no relevant financial relationships with ineligible companies to disclose.

Dr. Kumar has the following relevant financial relationships with ineligible companies: Consultant: Boston Scientific; Paid Speaker: Penumbra. All of the relevant financial relationships listed have been mitigated.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.